Loading...

NLS

NLSP

NLS PHARMACEUTICS LTD

(NLSP)

2024 6-K

Show Summary

Summary

Merger Agreement Update

29 Aug '25

Meeting Rescheduled

25 Aug '25

Warrant Exchange Agreement

6 Aug '25

Merger Update

18 Jul '25

Progress Update

17 Jul '25

Shareholders Meeting Results

1 Jul '25

Merger Amendment

1 Jul '25

Equity Financing Events

30 Jun '25

CEO Shareholder Letter

16 Jun '25

Shareholder Meeting Notice

10 Jun '25

Merger Agreement Update

6 Jun '25

Merger Extension

5 May '25

Director Resignation

24 Apr '25

Positive Study Results

15 Apr '25

Funding Amendment

4 Apr '25

Funding Announcement

31 Mar '25

CEO Letter Issued

10 Mar '25

Preclinical Data Release

27 Feb '25

FDA Meeting Success

25 Feb '25

Diabetes Approach Unveiled

10 Feb '25

Merger Amendment

31 Jan '25

Merger Announcement

31 Jan '25

Research Submission Update

30 Jan '25

Preclinical Program Launch

28 Jan '25

Merger Announcement

16 Jan '25

Shareholder Meeting Results

14 Jan '25

Fundraising Update

8 Jan '25

Shareholder Meeting Results

7 Jan '25

Proposed Merger

30 Dec '24

Extraordinary Meeting Notice

23 Dec '24

Shareholder Meeting Notice

19 Dec '24

FDA Meeting Request

19 Dec '24

Shareholder Meeting Notice

17 Dec '24

Shareholder Letter Issued

11 Dec '24

Share Capital Update

10 Dec '24

Private Placement Financing

4 Dec '24

Preclinical Data Release

3 Dec '24

Innovative Drug Highlight

18 Nov '24

Board Resignation

15 Nov '24

Merger Agreement

12 Nov '24

Shareholder Meeting Results

8 Nov '24

Shareholders' Meeting

6 Nov '24

Merger Agreement

5 Nov '24

Merger Agreement

4 Nov '24

Compliance Regained

28 Oct '24

Debt Forgiveness Deal

22 Oct '24

Financial Report Update

18 Oct '24

Private Placement Update

15 Oct '24

Nasdaq Compliance Regained

11 Oct '24

Financing Reports

11 Oct '24

Nasdaq Compliance Regained

10 Oct '24

Shareholders Meeting Results

7 Oct '24

Record Date Change

1 Oct '24

Share Capital Update

25 Sep '24

Shareholders' Meeting

19 Sep '24

Warrant Amendment

16 Sep '24

License Termination

13 Sep '24

Shareholder Meetings

26 Aug '24

Auditor Change

15 Aug '24

Management Change

14 Aug '24

Merger Announcement

30 Jul '24

Registered Offering Details

1 Jul '24

Positive Results

27 Jun '24

Shareholder Meeting Notice

25 Jun '24

Extension Granted

25 Jun '24

Patent Application Filed

11 Jun '24

Shareholder Meeting Notice

6 Jun '24

Management Change

31 May '24

Positive Study Results

28 May '24

Delisting Notice

24 May '24

Bridge Loan Update

22 May '24

Loan Agreement Update

14 May '24

Delisting Announcement

19 Apr '24

Share Capital Increase

15 Apr '24

Board Resignation

8 Apr '24

Funding Announcement

21 Mar '24

Debt Notifications

20 Mar '24

Exclusive License Agreement

20 Mar '24

Loan Agreements Update

19 Mar '24

Share Capital Increase

14 Mar '24

Listing Compliance Plan

11 Mar '24

Nasdaq Compliance Plan

23 Feb '24

Nasdaq Deficiency Notice

12 Jan '24

External Links:

SEC

On June 11, 2024, NLS Pharmaceutics Ltd. announced the publication of a new patent application for its next-generation dual non-sulfonamide orexin receptor agonists (DOXA). This filing is significant for the company, highlighting its innovation strategy and potential future developments.

AI Assistant

NLS PHARMACEUTICS LTD

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.